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ABSTRACT 
 
Crude extracts from Myrothamnus flabellifolius were fractionated through various 
chromatography techniques in order to achieve satisfactory separations. Two compounds, 
arbutin and lupeol, were isolated from the butanol and ethyl acetate extracts, respectively. 
Structural elucidation of the compounds was carried out on the basis of 
1
H and 
13
C NMR 
spectroscopy. It was the first time that lupeol had been isolated from M. flabellifolius.  
The water extract was found to contain heterogeneous pectic polysaccharides. Three 
polysaccharide fractions were separated from the water extract, namely; MPS, MPS-I and 
MPS-II. The predominant fraction was found to be MPS, with a molecular weight 
distribution of 2 X 10
5
 Da. The polysaccharides were made up the following 
monosaccharides; arabinose, rhamnose, xylose, mannose, galactose and glucose.  
Monosaccharide composition was determined through acid hydrolysis at high temperatures, 
followed by GC analysis. The linkage analysis was carried out by GC-MS, following partial 
methylation of the polysaccharides. 
 
The use of human serum albumin (HSA) following its anchoring on magnetic nanoparticles, 
in order to isolate targeted saponins from Sutherlandia frutescens led to successful isolation 
of four saponins, namely; sutherlandiosides A-D. The saponins showed great affinity to bind 
to the HSA. 
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CHAPTER 1 
Introduction and Literature review 
 
Plant chemistry or phytochemistry is an area of study which focuses on the investigation of 
the natural product composition of plants. Over the years, phytochemistry has developed as a 
bridge that connects chemistry and botany, as it also seeks to explain natural product 
biosynthesis, metabolism and biological function. 
 
1.1 Natural Products 
Natural products derived from plants are known to have different uses that are important to 
humans. Some of these natural products possess pharmacological or biological activities 
which may be exploited in pharmaceutical drug discovery and drug design. Others may be 
used in the preparation of food supplements, antioxidants, insecticides, etc. Given the above 
mentioned benefits, scientists began to do research on natural products in the early nineteenth 
century. Friedrich Sertürner isolated morphine (see Figure 1) from Papaver somniferumin in 
1806, and since then natural products have been extensively screened for their medicinal 
purposes. Among the first natural products to be isolated, were atropine and strychnine (see 
Figure 1). In 1826, E. Merck manufactured the first commercially pure natural product, 
morphine (Newman et al., 2000). 
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Morphine Strychnine  
Atropine 
Figure 1: Some of the first natural products to be isolated from plants.  
In modern medicine, about 41% of new and approved drugs have natural products as their 
origin, either directly or indirectly as shown in Figure 2 (Cragg et al, 1997). 
 
 
Figure 2: The role of natural products in modern medicine. 
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A close look at the anticancer drugs on the market today (Figure 3), shows that the 
percentage of new anticancer drugs which originated from natural products increased to about 
60% (Cragg et al, 1997). Between the years 1981-2006, about a hundred anticancer agents 
have been developed, of which twenty five are semisynthetics, eighteen are natural product 
based synthetics and twenty are pure natural products (Newman et al, 2007). 
 
 
Figure 3: The role of natural products in anticancer drugs. 
 According to Van Wyk et al. (2000), the use of natural products in medicine is justified since 
they are the main active substances in medicinal plants that act in the treatment or prevention 
of diseases, either directly or indirectly (e.g. see Table 1). Over the years, more studies 
carried out on natural products have led to the discovery of diverse compounds with unique 
properties. Furthermore, advances in technology have guaranteed great improvement in 
relation to extraction, isolation, purification and structural elucidation of these compounds.  
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Table 1: Some examples of prescription drugs from the plant kingdom. 
Name of drug Plant source Medical use  
Morphine Papaver somniferum Analgesic  
Betulinic acid Betula alba Anticancer  
Taxol Taxus brevifolius Anticancer  
Quinine Cinchona pubescences Antiprotozoal/malaria  
Cocaine Erythoxylum coca Anaesthetic  
Hyoscine Datura stramonium Sedative  
Atropine Datura stramonium Analgesic  
Vincristine Catharanthus roseus Leukaemia  
 
Some of these compounds have important applications in other fields such as cosmetics and 
food industries, organic synthesis, etc. For example, quinine from Cinchona pubescences is 
known to give tonic water that bitter taste. In addition, herbs and spices have long been 
known to provide flavour to foods. 
 
1.2 Classification of natural products 
Natural products consist of all organic compounds which are produced as a result of the 
natural processes that plants are subjected to. In the initial stages, these processes are driven 
by light energy (from the sun) which is then stored for further use by the plants. Natural 
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products may be divided into two categories: primary and secondary metabolites. Primary 
metabolites are compounds that are mostly present in every living cell, and which posses 
structural, reproductive and metabolic functions. Some examples of primary metabolites 
include: carbohydrates, cellulose, amino acids and proteins. On the other hand, secondary 
metabolites are not present in all living organisms. These compounds usually have diverse 
biological effects on other organisms. Some various classes of secondary metabolites that are 
known include: terpenoids, glycosides, tannins, alkaloids, phenolics, etc. 
 
1.3 Some natural products isolated from the plant kingdom 
1.3.1 Glycosides 
Glycosides are compounds which have a carbohydrate that is attached to a non-carbohydrate 
moiety through an acetal linkage. Upon hydrolysis, glycosides release a saccharide unit 
(glycone) and a non-carbohydrate moiety (aglycone). When the carbohydrate part is glucose, 
the compound is usually called a glucoside or a fructoside in cases where it is fructose. 
Aglycones may be any class of natural products from sterols, phenolics, triterpenoids, etc. 
Glycosides are very important because of the various biological activities they posses, e.g. 
saponins (steroidal glycosides) from Dioscorea nipponica are believed to be the active 
ingredients in the plant’s use in the treatment and prevention of coronary heart disease (Qing 
et al., 2010). A well known glycoside, rutin, from Carpobrotus edulis is responsible for the 
plant’s antibacterial (Van der Watt and Pretorius, 2001) and antioxidant properties (Ibtissem 
et al., 2012). In the market, rutin is available as a drug used in the treatment of veins fragility.  
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1.3.2 Terpenoids 
Terpenoids represent a major class of natural products, with over ten thousand compounds 
which are derived from an isoprene unit (C5H8). Depending on the number of isoprene units, 
terpenoids may be classified into: hemiterpenoids (1 unit), monoterpenoids (2 units), 
sesquiterpenoids (3 units), diterpenoids (4 units), sesterpenoids (5 units), triterpenoids (6 
units), tetraterpenoids (8 units), and polyisoprenes (more than 8 units). Terpenoids play a 
very important role, therapeutically, in traditional herbal remedies due to their 
pharmacological activities, e.g. a monoterpenoid called menthol is a very popular pain 
reliever. Another example is a popular anticancer drug called taxol, a diterpenoid first 
identified in Taxus brevifolia. Terpenoids are mostly found to exist in the triterpenoid form. 
Some interesting triterpenoids occur in Sutherlandia frutescens, a very popular medicinal 
plant indigenous to South Africa, where they act as protection against viral infections. 
Katerere et al. (2003) reported that some pentacyclic triterpenes isolated from members of the 
African Combretaceae expressed antimicrobial activity against Mycobacterium fortuitum and 
Staphylococcus aureus. Lee et al. (1989) reported that triterpenes and their derivatives 
expressed in vitro cytotoxicity to tumor cell lines. Fujioka et al. (1994) reported that a 
triterpenoid, betulinic acid, isolated from the leaves of Syzigium claviflorum expressed anti-
HIV activity. 
 
1.3.3 Essential oils 
Essential oils are a mixture of aromatic, volatile compounds which are insoluble in water, 
such as monoterpenoids, sesquiterpenoids and their derivatives. Plants containing essential 
oils are traditionally known to express anticarcinogenic, astringent and anti-inflammatory 
effects (Lovkova et al., 2001). 
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1.3.4 Phenolic compounds 
Phenolic compounds are a major group of compounds found in plants, which may be 
classified according to their water solubility. There is a class of soluble phenolic compounds 
which includes flavonoids, quinones, anthocyanins, etc. Another class consists of water-
insoluble phenolic compounds such as tannins. Flavonoids are a major group within the 
phenolics class of compounds (see Figure 4), and they are synthesized via the shikimic acid 
pathway. Flavonoids are constituents of vegetables, fruits and other plant types and parts. The 
widespread distribution of flavonoids, their variety and their relatively low toxicity compared 
to other active plant compounds (for instance alkaloids) suggest that many animals, including 
humans, ingest significant quantities in their diet. Therefore, flavonoids are often used as 
dietary substances for health promotion, anti-ageing and disease prevention (Fernandes et al., 
2004). Flavonoids are known to produce the colour pigmentation in flowers and fruits, which 
is sometimes regarded as a defensive mechanism against attacks from insects and microbes. 
Some of the major types of flavonols such as quercetin have been isolated in plants such as 
Butea frondosa. Cancer researchers have reported that study participants who consumed 
foods containing certain flavonoids appeared to be protected from developing lung cancer 
(David, 2007).  Some of the flavonoids that seemed to offer the most protection include 
quercetin, and only small amounts of these flavonoids are required to provide health benefits. 
Flavonoids have also been reported to be present in Sutherlandia frutescens. Due to the large 
variety of phenolic compounds, medicinal plants exhibit a variety of pharmacological and 
therapeutic effects, e.g. flavonoids act as antioxidants (Sigh et al., 2005), among many others. 
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Figure 4: Some classes of flavonoids found in medicinal plants. 
 
1.3.5 Polysaccharides 
Polysaccharides are polymers that yield many monosaccharide molecules when hydrolyzed, 
e.g. starch yields glucose molecules. Starch is the main source of energy in plants. Starch is 
composed of two types of polysaccharides, amylose and amylopectin. Amylose is a linear 
polymer composed of glucose residues with (1→4) linkages, while amylopectin consists of 
(1→4) linkages and ∼5% (1→6) branch linkages. Polysaccharides are important natural 
products because they offer great benefits to human health. Kouakou et al. (2013) reported 
that polysaccharides from an African plant Clerodendrum splendens expressed 
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immunomodulatory activity. A β-glucan found in mushrooms was reported to exhibit some 
antitumor properties (Ren et al., 2012), and so were the polysaccharide-protein complexes 
from mushrooms (Ooi and Liu, 2000). Zhao et al. (2007) reported that polysaccharides 
islated from Dendrobium chrysotoxum expressed antioxidant and anti-hyperglycemic 
activity. 
Some polysaccharides are composed of acidic monosaccharides, i.e. monosaccharides that 
contain the carboxylate ion, COO
-
. Pectins fall within this type of polysaccharides. Pectins 
have a characteristic backbone in which 1,4-linked galacturonic acid units have a “kink” due 
to rhamnogalacturonan regions made up of a backbone of alternating 1,2-linked rhamnose 
and 1,4-linked galactose units (Van Soest, 1994). Neutral side chains are mostly substituted at 
O-4 of the rhamnose units, and consist of arabinose and galactose units. 
There is also a class of polysaccharides known as arabinogalactans. Arabinogalactans are 
generally divided into two structural types. Type I is mainly pectic arabinogalactans which 
consist of a principal chain of 1,4-linked galactose units with arabinosyl units occurring as 
substituents (Clarke et al., 1979; Stephen, 1983). The arabinosyl units are linked to galactose 
units through O-3. Type II arabinogalactans are highly branched polysaccharides made up of 
1,3-linked and 1,6-linked galactose units, with the 1,6-linked units mostly found in the 
exterior and the 1,3-linked found in the interior of the main chain. The arabinose units are 
sometimes attached to the through O-3 of the 1,6-linked galactose units.    
Pectic polysaccharides are known to exhibit some important biological activities. In cosmetic 
and food industries, pectin extracts from fruits such as apples and citrus peels are known to 
function as stabilizing and gelling agents. Krachanova et al. (2010) reported that the pectic 
polysaccharides isolated from Allium porrum exhibited immunostimulating activities. Pectic 
polysaccharides isolated from Mosla chinensis have been reported to show considerable 
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antitumor activity, as well as inhibition of NO production (Li et al., 2014). As part of the 
daily fibre intake, pectins have been reported to lower blood cholesterol levels (Sriamornsak, 
2001), and remove toxic cations from the respiratory organs and gastrointestinal tract (Kohn, 
1982). Thakur et al. (1997) have reported some antimicrobial activity of pectins towards 
Echerichia coli.  
 
1.4 Medicinal plants 
According to Sofowora (1982), a medicinal plant is defined as any plant that can be used in 
the treatment of diseases or ailments because it contains, in any of its parts, natural products 
that have biological activity against such diseases or ailments. Medicinal plants also play a 
significant role in the development of medical drugs since most of the modern medicines owe 
their origins to plants. Natural products extracted or isolated from plants are used as 
precursors or blueprints for the synthesis of synthetic or partially synthetic drugs (Simpson 
and Ogorzaly, 2001).   
 
Despite the technological advances in modern medicine, the majority of the world’s 
population still depend on the use of medicinal plants for health care purposes. For example, 
in South Africa, about 80% of the total population rely fully or partly on medicinal plants for 
their health care needs (Balick et al., 1994). This reliance on medicinal plants may be 
attributed to the cultural and religious practices of some ethnic groups, which the indigenous 
plants form an integral part thereof. Additionally, this sort of health care system is easily the 
most accessible and affordable to those poor communities who have difficulties accessing 
commercial drugs. Across the first world countries, about 1500 medicinal plants are used in 
the form of herbal remedies and drugs (Hoareau and DaSilva, 1999).  
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Over the recent years, there has been a noticeable increase in the consumption of herbs and 
drugs from medicinal plants. The World Health Organization (WHO) has reported that, in 
Africa, more than 60% of infants are entirely dependent on medicinal plants for the treatment 
of malaria and fever (Diarra, 1999). This has prompted the South African Ministry of Health 
to embark on a promotional campaign for the consumption of medicinal plant extracts. Two 
of the most championed medicinal plant species, currently, are Sutherlandia frutescens and 
Hypoxis hemerocallidea. These plant species have shown a great deal of potential in the 
management or treatment of diseases such as cancer and HIV (Mills et al., 2005). S. 
frutescens, a plant which has been used in this thesis as a model to explore one of the newer 
approaches to the study of medicinal plants, is a plant which has a wide range of medical uses 
without any reported toxicity or side effects associated with its use. The powdered or 
encapsulated S. frutescens is distributed by Phyto Nova, a South African pharmaceutical 
company. Another company, Parceval Pharmaceuticals, manufactures “Power-Your-Life” 
tablets and an immune-boosting syrup, both of which are derived from S. frutescens extracts 
(www.parceval.co.za). 
 
A complete contrast to what has long been seen as a primitive and unconventional practice, 
the use of medicinal plants has now become more commercialized. More and more 
pharmaceutical companies have undertaken to the processing, distribution and selling of 
herbs or natural products, with the assistance of some media coverage (Brevoort, 1998). 
Inevitably, both the local and international trades have increased due to the demand of 
medicinal plant based products. Medicinal plants are not only cheaper than synthetic drugs, 
but they also have far greater value in the export trade. WHO has estimated that 
pharmaceutical companies around the world attract the equivalent of billions of US dollars in 
annual gross profits. According to Aarts (1998), the sales of Hypericum perforatum, a 
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medicinal plant used as a treatment for depression, went up exponentially in the space of a 
year. Large quantities of a highly popular medicinal plant in the food industry, Agathosma 
spp. (Buchu), are being exported around the world. 
 
1.5 Ligand fishing 
Ligand fishing is a recently introduced methodology, which relies on the ability of bioactive 
molecules contained in crude extracts to selectively and reversibly bind to certain biological 
macromolecules, which in most cases represent the so-called protein receptors. This process 
is generally designed for the purpose of triggering off a cascade of biochemical reactions in 
the relevant organism, or to facilitate the transportation of certain molecules in the blood 
stream, depending on the location of the receptor in question. Given that most plant extracts 
are mostly likely to contain compounds with these characteristics and capacity, it should be 
considered worthwhile to include this method as one of the routine ways of studying 
medicinal plant extracts 
In drug discovery and drug development, the receptor theory accounts for mechanism of drug 
action, and the relationship of drug action to its molecular structure (Brenner and Stevens, 
2006). Ligand fishing is a method, therefore, that uses the principles of the receptor theory to 
screen cellular and botanical extracts for potential ligands. The ligands may be of orphan or 
known receptors. Ligand fishing is thus very useful in detecting bound ligands (bioactive 
substances) from botanical extracts (Catimel et al., 2000).  
 
In a study by Qing et al. (2010), saponin ligands from Dioscorea nipponica were investigated 
for their binding capacity to human serum albumin (HSA), using HSA functionalized 
magnetic particles (MNPs). HSA is understood to be the most abundant protein in human 
blood plasma, where its function is the transport and deposition of ligands (Yamasaki et al., 
 
 
 
 
13 
 
1996). It has a three-dimensional structure with multiple coordination sites for different 
ligands, including fatty acids, amino acids, drugs and hormones (Carter and Ho, 1994). 
Binding affinity towards HSA determines the ligands’ overall distribution, metabolism and 
efficacy; therefore a study into their binding capacity to HSA is very important. In chemical 
and biological sciences, MNPs owe their wide applications to three properties: suspension 
stability, easy solid-liquid separation, and easy surface modification. Ligand fishing based on 
MNPs has broad applications in the purification of proteins. 
Qing et al. (2010) discovered that three saponin ligands from a Dioscorea nipponica ethanol 
extract demonstrated a binding affinity to HSA. Of the five saponins previously detected in 
the extract, two showed no affinity at all towards HSA. Qing et al. (2010) concluded that 
binding affinity towards HSA is highly dependent on the chemical structure of the ligand and, 
therefore, medicinal applications, since it may be imagined that possibly, only those ligands 
with a capacity to bind to HSA are likely to be distributed in the blood stream, and hence able 
to reach the remote tissues or organs where they are expected to express activity. 
 
1.6 Plant species studied in this thesis 
 
1.6.1 Myrothamnus flabellifolius 
There are some plant species that have, over the years, acquired a rare ability to tolerate 
regular periods of severe dehydration (desiccation), and yet resume full metabolic activity on 
rehydration (Gaff, 1971). These plants are generally called resurrection plants. Southern 
Africa has a rich diversity of resurrection plants. Among these, Myrothamnus flabellifolius 
(resurrection bush in English, Moritela Tshwene in Setswana, Opstandingsplant/Bergboegoe 
in Afrikaans, Vukwabafile in Zulu) is a woody shrub which stands at 0.4 m in height, with 
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strong, rigid branches. The plant has very small aromatic leaves that are toothed on the 
margins, and the plant usually grows in rocky areas as shown in Figure 5. 
 
Figure 5: Myrothamnus flabellifolius in habitat on a: A) dry season and B) rainy season. 
 
Myrothamnus is the only genus that belongs to the family Myrothamnaceae, a family of 
flowering plants. There are two currently known Myrothamnus species, namely: 
Myrothamnus flabellifolius and Myrothamnus moschatus.   
Myrothamnus flabellifoolius is distributed throughout the rocky areas of Namibia, Botswana, 
South Africa (North Western part of the North West Province and Limpopo) and Zimbabwe. 
The leaves of the plant have a strong aromatic character, and together with the twigs are used 
in many medicinal preparations. Traditionally, the leaves of M. flabellifolius are burnt and the 
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smoke inhaled to treat chest pains and asthma, or the leaves are smoked in pipes. Some 
people chew the aromatic leaves for the treatment of mouth ailments, and some traditional 
healers use the plant to treat epilepsy, madness and coughs. M. flabellifolius has long been 
used as a nutritional herbal tea by the community of the Mokgola Village near Zeerust (North 
West Province, South Africa). The plant is taken as a tea with some reported minor health 
benefits. However, little is known about the nutritional content, the safety, the antioxidant 
properties, and the carbohydrate content of the plant. Studies on these topics, and more, could 
assist with the development of a branded commercial herbal tea which may be marketed both 
locally and internationally. In turn, commercialization of this tea should contribute to the 
economy of the Mokgola community (and that of the country), thus alleviating poverty in the 
area. 
 
1.6.1.1 Previously isolated compounds from M. flabellifolius 
High polyphenol (tannins) levels have been reported to be present in the leaves of 
Myrothamnus flabellifolius (Moore et al., 2007). The most predominant polyphenol was 
found to be 3,4,5 tri-O-galloylquinic acid (Moore et al., 2005).   
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3,4,5 tri-O-galloylquinic acid  
Moore et al. (2005) further suggested that 3,4,5 tri-O-galloylquinic acid is the main 
compound that is responsible for providing protection to the plant against dying from 
desiccation, in addition to its free radical scavenging properties. The leaves of the plant have 
also been reported to contain a disaccharide called trehalose, which is also known to provide 
protection against desiccation, due to its high water retention capabilities (Moore et al., 
2007).  
OH
HO
HO
O O
OH
OH
OH
OH
O
OH
Trehalose 
Van Wyk et al. (2002) also reported about 85 compounds contained in the hydro-distilled 
essential oils, with pinocarvone and trans-pinocarveol being identified as the major 
constituents in the oil. 
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O
Pinocarvone                            
OH   trans-pinocarveol 
 
A qualitative phytochemical screening conducted by Molefe-Khamanga et al. (2012a), on the 
leaves of M. flabellifolius, revealed the presence of phenolics, tannins, alkaloids, flavanoids, 
reducing sugars, steroids, proteins and amino acids in both the methanol and water extracts. 
Such chemical composition, as observed in M. flabellifolius, may be implicated in a number 
of biological activities exhibited by the plant (see Table 2). In a separate study, Molefe-
Khamanga et al. (2012b) reported that extracts from M. flabellifolius do not contain any 
caffeine, and hence the plant may be classified as a source of naturally caffeine free tea, thus 
making it suitable as a health tea. 
However, M. flabellifolius shows differences in its chemical composition depending on the 
location, the nature of the soil and climate in which the plant grows. Previous studies have 
shown differences in the polyphenol composition between the South African and Namibian 
populations (Moore et al., 2007). 
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Table 2: Reported biological activities of compounds and extracts from M. flabellifolius. 
Biological activity Part(s) of the plant Compound(s) References 
Anti-HIV reverse 
transcriptase 
Leaves and twigs 3,4,5tri-O-
galloylquinic acid 
Moore et al., 2005 
Antioxidant Leaves 
Water extract 
Trehalose 
 
Moore et al., 2007 
Motlhanka and 
Mathapa, 2012 
 
1.6.2 Sutherlandia frutescens 
Sutherlandia frutescens (syn. Lessertia frutescens (L.), Colutea frutescens L.) is a flowering 
plant which belongs to the family Fabaceae, the second largest flowering plant family in the 
world (see Figure 6). In nature, S. frutescens is a woody, shrubby plant which possesses red 
flowers and slightly hairy leaves that appear silvery (Van Wyk et al., 1997). The plant grows 
to an approximate height of 1m. S. frutescens is widely distributed in the dry regions of South 
Africa (Western Cape and the Karoo region), Namibia and Botswana. The plant is very 
popular amongst different cultural groups, hence it is known by a variety of vernacular names 
such as: “cancer bush, Sutherlandia, scarlet balloon pea” (English), “kankerbossie, gansies, 
grootgansies” (Afrikaans), “umnwele” (Xhosa), “insiswa” (Zulu), “lerumo-lamadi, musapelo, 
motlepelo” (Sesotho), “phetola” (Tswana).  
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Figure 6: Leaves and flowers of the S. frutescens plant (www.treknature.com). 
The Zulu name, “insiswa”, which means “dispels darkness”, was conceived due to the ability 
of S. frutescens to alleviate depression and sadness (Van Wyk and Albrecht, 2008). Some 
hundred years ago, Zulu women used this plant as a gentle tranquilizer/antidepressant when 
grieving the loss of their warrior spouses in wars. The warriors themselves used it to relax 
and recover. The Tswana name, “phetola”, which means “to change”, also alludes to the 
ability to alleviate stress related conditions. The first people to use the plant for medicinal 
purposes, however, were the Khoi San and Nama people, who used it primarily as a 
decoction for washing wounds and also took it internally to reduce fevers. Traditional healers 
have long used the plant in the treatment of a number of ailments, such as asthma, cancer 
(prevention and treatment), poor appetite, HIV/AIDS, cachexia (muscle wasting), diabetes, 
fever, colds, cough, influenza, indigestion, heartburn, heart failure, peptic ulcers, kidney and 
liver ailments, urinary tract infections, etc (Van Wyk and Albrecht, 2008). The leaves of the 
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plant are the most commonly used, but other aerial parts can also be used in making 
decoctions (Van Wyk, 1997). 
The commercially available S frutescens contains only selected leaves and tender stems 
(Brevoort, 1998). Other parts of the plant such as flowers, pods and seeds are discarded. 
During processing, the leaves and stems are dried and ground into a powder. In retail shops, 
S. frutescens may be found as capsules which have been gamma irradiated so as to eliminate 
microbiological contamination. The recommended daily therapeutic dosage of S. frutescens is 
9.0 mg/kg body weight per day in humans (Seier et al., 2002). In South Africa, a 
pharmaceutical company called Phyto Nova is the major distributor of commercial products 
derived from S. frutescens.  
 
1.6.2.1 Previously isolated compounds from S. frutescens 
The biological activities of S. frutescens may be attributed to the presence of a variety of 
biologically active compounds. Some of the compounds which have been isolated from 
S.frutescens include; pinitol, L-canavanine, gamma-aminobutyric acid (GABA), triterpenoid 
glycosides, flavanol glycosides, and more (Fu et al., 2010; Van Wyk and Albrecht, 2008). 
 
Pinitol 
Early studies by Snyders (1965), Viljoen (1969) and Brummerhoff (1969) on Sutherlandia 
microphylla leaves, showed the presence of a mono-methylated form of D-chiro-inositol 
called pinitol (also called 3-O-methyl-chiro-inositol) for the first time.  
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     Pinitol 
The recorded bio-activities of pinitol make it a potentially important compound in the context 
of the traditional uses of Sutherlandia against diabetes and inflammation (Moshe, 1998). 
Besides acting as an anti-diabetic agent, pinitol is also used in the treatment of wasting in 
cancer and AIDS patients (Ostlund and Sherman, 1996). It has also been documented that 
pinitol exerts an acute and chronic insulin-like effect (hypoglycaemic effect), resulting in 
lower blood sugar levels and increased availability of glucose for cell metabolism (Bates et 
al., 2000), and enhances the retention of creatinine by muscle cells (Greenwood et al., 2001). 
Overall, pinitol therefore seems to play a role in regulating cellular energy, resulting in 
increased energy levels and a reduction in fatigue (Van Wyk and Albrecht, 2008).  
 
L-canavanine 
L-canavanine is a non-protein amino acid, most commonly found in the seeds of the family 
Fabaceae.  
NH2
O
H
N
NH
H2N
O
OH
 L-canavanine 
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The detection of L-canavanine in high concentrations in the Sutherlandia leaf extracts 
(Moshe, 1998), provided some justification for the traditional use of Sutherlandia against 
cancer. L-canavanine has been reported to have anti-cancer as well as anti-viral activity, 
including inhibition of the influenza virus and retroviruses, such as HIV (Green, 1988). 
Sutherlandia is the first known canavanine-containing plant for which anticancer activity has 
been documented (Bence et al., 2002; Van Wyk and Albrecht, 2008).  
 
Gamma-aminobutyric acid (GABA) 
Gaba is an amino acid which is a product of decarboxylation of glutamate by the enzyme L-
glutamic acid-1-decarboxylase (Ebadi, 2007). 
  
O
OH
NH2
GABA 
 
Gaba acts as an inhibitory neurotransmitter which, together with inositol and nicotinamide, is 
responsible for blocking anxiety and stress related impulses from reaching the motor centers 
of the brain. In cases of epilepsy and hypertension, Gaba induces calmness in patients 
(www.anyvitamins.com). As such, Namaqualand residents are reported to smoke 
Sutherlandia seeds and leaves as a dagga substitute, with the leaves invoking a strong 
GABA-induced sedative effect when smoked (Van Wyk and Gericke, 2000). GABA has also 
been found to inhibit tumour cell migration (Ortega, 2003).  
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Free Amino Acids 
The leaf extracts of Sutherlandia contain high concentrations of free and protein-bound 
amino acids, such as L-arginine, L-asparagine and proline (Van Wyk and Albrecht, 2008), 
whose structures are shown below. The presence of L-arginine is particularly important, 
because it acts as an antagonist of L-canavanine that reduces the anti-proliferative activity of 
canavanine. 
 
NH2
H
N
NH
H2N
O
OH
L-arginine                                        
NH2 O
NH2
O
HO
 L-asparagine 
 
Saponins 
Brummerhof (1969) and Viljoen (1969) detected the presence of triterpene glycosides in 
Sutherlandia microphylla, but the compounds were not characterized. A phytochemical study 
of S. frutescens conducted by Fu et al. (2008), led to the isolation and identification of four 
cycloartane-type triterpene glycosides, namely; Sutherlandioside A, B, C and D. These 
saponins have a bitter taste that may stimulate appetite and contribute to the adaptogenic and 
immune-boosting effects of Sutherlandia. Sutherlandioside B, C and D are the first examples 
of naturally occurring cycloartanes with a C-1 ketene function, but the exact role they play in 
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phytotherapy is still unknown (Fu et al., 2008). The major triterpene in commercially 
available S. frutescens, is sutherlandioside B shown below.  
HO
O
OH
O
O
OH
OH
OH
HO
OH
Sutherlandioside B 
 
Flavonol glycosides 
In a study conducted by Moshe (1998), at least six flavonoids were detected in the leaf 
extracts of Sutherlandia. Four of these were subsequently identified as flavonol glycosides; 
Sutherlandin A, B, C and D (Fu et el., 2010). Flavonoids are important in phytotherapy 
because they possess anti-oxidant activity, and may play a critical role in cancer prevention 
through the ability to eliminate mutagens and carcinogens (Tai et al., 2004). A typical 
structure of one of the flavonol glycosides isolated from S. frutescens is shown below. 
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Other compounds 
High concentrations of unidentified polysaccharides have been reported in aqueous leaf 
extracts from S. frutescens (Van Wyk and Albrecht, 2008). Hexadecanoic acid, γ-sitosterol, 
stigmast-4-en-3-one and at least three long chain fatty acids have also been reported (Tai et 
al., 2004). 
 
1.6.2.2 Biological properties of S. frutescens extracts. 
Most medicinal plants owe their toxicity to one or a combination of the following factors; 
type of metabolites present in the plants, contaminants, adulterants, and their interaction with 
other plant constituents or drugs. In terms of traditional use, history shows that S. frutescens 
is one of the safest plants to use, with only a few reported side effects associated with its use. 
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Some of the reported side effects include dry mouth, occasional mild diarrhea, dizziness and 
mild dieresis (Mills et al., 2005).  
 
In a study conducted by Ojewole (2004), it was demonstrated that the crude extracts from S. 
frutescens are relatively safe to use in mammals. In addition, an extensive toxicology study 
which was carried out on vervet monkeys using higher doses than the recommended daily 
dose (9.0 mg/kg) clearly showed that S. frutescens did not exhibit any significant clinical or 
physiological toxicity (Seier et al., 2002). However, studies on the long term use of plant 
extracts have yet to be documented. It is advised that during pregnancy, use of S. frutescens 
extracts should be avoided. 
The pre-isolated compounds from S. frutescens are known to evoke a few pharmacological 
effects and recent scientific interest has led to the identification of several biological targets 
(Table 3). 
 
Table 3: Some reported biological activities of compounds and extracts from S. 
frutescens. 
Biological activity Part(s) of the 
plant 
Compound(s) or 
extract 
References 
Anti-diabetic Leaves Pinitol 
L-canavanine and L-
arginine 
Aqueous extract 
Moshe et al., 1998; Bates 
et al., 2000; Sia, 2004; 
Ojewole, 2004 
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Biological activity Part(s) of the 
plant 
Compound(s) or 
extract 
References 
Anti-cancer Leaves L-canavanine 
Triterpenoids 
Ethanolic extract 
Dichloromethane 
(DCM) extract 
Van Wyk and Gericke, 
2000; Seier et al., 2002; 
Tai et al., 2004; Reid et 
al., 2006; Kikuchi et al., 
2007 
Anti-HIV Leaves Aqueous and Organic 
extracts 
Gericke et al., 2001; 
Chaffy and Stokes, 2002; 
Harnett et al., 2005; 
Bessong et al., 2006; 
Johnson et al., 2007; 
Katerere and Rewerts, 
2011 
Anti-inflammatory 
and antibacterial 
Leaves Aqueous and hexane 
extracts 
Flavonol glycosides 
L-canavanine 
Green, 1988; Fernandez et 
al., 2004; Ojewole, 2004; 
Katerere and Eloff, 2005 
Stress Leaves Gaba 
 
Prevoo et al., 2004; Sia, 
2004; Smith and Myburgh, 
2004;Tai et al., 2004 
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1.7 Problem statement 
Africa is one of the richest continents with respect to biodiversity, blessed with well over 50 
000 different plant species. Many of these plants have been found to be very useful in 
traditional medicine, on which about 80% of the continent’s population fully or partly relies 
for primary health care needs. However, only a few of these medicinal plant species have 
been commercialized as branded medical products. According to Van Wyk and Wink (2004), 
Africa has only 83 medicinal plants that have been fully or partly commercialized. This can 
be attributed to a lack of extensive research studies and development activity conducted on 
most of the plants. As such, safety issues on how to handle or administer the crude extracts 
from these plants are not fully understood, and this problem extends to their pharmacological 
efficacy and activity. M. flabellifolius is just one of the plant species that has not been 
commercialized. Traditionally, M. flabellifolius has been used as a nutritional herbal tea, and 
in the treatment of a variety of ailments including asthma, epilepsy, etc. Thus, chemical 
studies on M. flabellifolius may lead to the isolation of some bioactive natural products, 
which may be used as precursors in the synthesis of new drugs. 
 
An example of a commercialized medicinal plant is S. frutescens, a southern African plant 
popularly used in the treatment and prevention of cancer and HIV. The plant contains 
compounds which are believed to have anticancer and anti-HIV properties. However, the 
mode of action related to these activities is not well understood. Since it is believed that 
bioactive compounds ought to be transportable in the blood stream and hence have the 
capacity to bind to human serum albumin (HSA), a part of this study was designed to 
investigate the use of magnetic nanoparticles on which HSA is anchored, in order to examine 
whether these compounds would readily bind to HSA. 
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1.8 Hypothesis 
As a result of the high cost of drugs, and the alarming rate at which drug-resistant pathogens 
are emerging, medicinal plants may be used as an alternative source to conventional drugs, 
thus taking advantage of the natural product constituents present in such plants. Hence, 
isolation and characterization of such compounds may contribute to a better understanding of 
their role or otherwise in relevant pharmacological activities. 
 
1.9 Aim of the study 
The aim of the study was to isolate and characterize the natural products from the leaves of 
M. flabellifolius and to use S. frutescens as a model plant to assess the capacity of selected 
compounds to bind to human serum albumin (HSA). 
 
1.10 Objectives of the study 
The specific objectives were to: 
1) Perform solvent extraction on the leaves of both M. flabellifolius and S. frutescens. 
2) Isolate and characterize natural products from the crude extracts of M. flabellifolius 
using chromatographic and spectroscopic techniques such as nuclear magnetic 
resonance (NMR) spectroscopy and mass spectroscopy (MS). 
3) To examine the capacity of selected compounds to bind to HSA. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Reagents and general methods. 
2.1.1 Reagents 
Solvents: n-hexane, dichloromethane, ethyl acetate, butanol, methanol, deuterated methanol 
and deuterated chloroform were purchased from Sigma-Aldrich, South Africa. FeCl3, 
Na2SO3, tetraethyl orthosilicate (TEOS), 3-aminopropyltrimethoxysilane (APTMS), coupling 
buffer (10mM pyridine, pH 6.0), human serum albumin (HSA), reaction-stop buffer (1M 
glutaric acid, pH 8.0), the wash buffer (10mM Tris, pH 7.4) and ammonium 10mM acetate 
buffer (pH 7.4) were all purchased from Sigma-Aldrich, South Africa. Dextran standards 
with molecular weights 10 000Da, 70 000 Da, 110 000 Da, 150 000 Da and 500 000 Da were 
purchased from Amersham Biosciences, Sweden. 
 
2.1.2 General methods 
2.1.2.1 Solvent Evaporation 
Solvent evaporation was performed on a Buchi Rotavapor RE 111, with the temperature of 
the water bath maintained at 45
0
C.  
 
 
 
 
 
 
 
31 
 
2.1.2.2 Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy  
NMR spectra were recorded on a Varian-200 NMR, Agilent-600 NMR at the University of 
Stellenbosch, and Bruker-600 NMR at the University of the Free State. The chemical shifts 
were expressed in δ (ppm), and coupling constants (J) in Hz. 
Fourier Transform -Infrared Spectroscopy (FT-IR Spectroscopy) 
IR spectra of powdered material were recorded on a Perkin–Elmer paragon 1000 
spectrometer that had been corrected against an air background, at a resolution of 3cm
-1
. 
 
2.1.2.3 Chromatography 
Column chromatography (CC) 
Silica gel 60 (0.040-0.063mm) 230-400 mesh particle size (Merck) was packed in glass 
columns (20-25mm diameter) for column chromatography. Size-exclusion chromatography 
was performed using Sephadex
®
 LH-20 (Pharmacia), eluting with MeOH:CH2Cl2 (1:1). Ion 
exchange chromatography of polysaccharide fractions was carried out using DEAE 
Sepharose CL-6B (Sigma Aldrich), eluting with 0.1-1.0M NaCl. Gel filtration 
chromatography was carried out using Sephacryl S-400 HR (Pharmacia), eluting with 1.0M 
NaCl. 
Thin layer chromatography (TLC) 
Thin layer chromatography was carried out on pre-coated silica gel 60 F254 plates (Merck) 
with a 0.2 mm layer thickness. Visualisation of the TLC spots was carried out under UV light 
at 254nm and/or 366nm, and further detection of compounds was achieved by spraying with 
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vanillin spray reagent (prepared by dissolving 15g of vanillin in 250ml ethanol followed by 
the addition of 2.5ml concentrated sulphuric acid). After spraying, the TLC plates were 
heated on a hot plate until spots became visible. 
 
2.1.2.4 Mass Spectrometry (MS) 
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass 
spectrometry (LC-MS) analyses were performed at the University of Stellenbosch Central 
Analytical Facility. 
LC-MS method 
LC-MS analysis was conducted on a Waters Synapt G2 quadrupole time-of-flight mass 
spectrometer. The instrument was connected to a Waters Acquity ultra-performance liquid 
chromatography (UPLC) and Acquity photo diode array (PDA) detector. Ionisation was 
achieved with an electrospray source using a cone voltage of 15V and capillary voltage of 2.5 
kV and positive mode was utilized. Nitrogen was used as the desolvation gas at 650 l/h and 
the desolvation temperature was set to 275˚C. A Walters UPLC BEH C18 column (2.1 x 50 
mm, 1.7 µm particle size) was used and 3µl was injected for each analysis. The gradient 
started with 100% using 0.1% (v/v) formic acid (solvent A) and this was kept 100% for 0.5 
min, followed by a linear gradient to 22% acetonitrile (solvent B) over 2.5 min, 44% solvent 
B over 4 min and finally to 100% solvent B for an additional 2 min. The column was then re-
equilibrated over 1 min to yield a total run of 25 min. A flow rate of 0.4 ml/min was applied   
GC and GC-MS method 
Separation of the monosaccharide derivatives was achieved on an Agilent 6890N GC 
instrument with CTC CombiPAL Autosampler and Agilent 5975B MS spectrometer with a 
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DB 225 capillary column (30 m x 0.25 mm internal diameter x 0.25 μm film thickness), 
Model Number:  J&W 122-2232, at 215°C isothermal temperature, FID detector at 300°C, 
injector temperature at 250°C and injector split 20:1. Positive ionisation mode was utilized 
and the flow rate was set at 2 ml/min.  
 
2.2 Plant material 
Powdered plant material of Myrothamnus flabellifolius was provided by the Medical 
Research Council (MRC) following collection from the Mokgola village, near Zeerust in the 
North West Province, South Africa. 
Sutherlandia frutescens powder was supplied by Afriplex, a commercial manufacturing 
company located in Paarl, South Africa. 
 
2.3 Preparation of extracts 
Extraction of both plant species, Myrothamnus flabellifolius (200g) and Sutherlandia 
frutescens (50g), was carried out as illustrated in Scheme 1. The powdered leaf material was 
extracted with methanol (MeOH). The methanol extract was evaporated to dryness under 
reduced pressure on a rotary evaporator. The dried extract was suspended in water and 
partitioned successively with hexane (Hex), dichloromethane (DCM), ethyl acetate (EtOAc) 
and butanol (BuOH). Each extract was concentrated to dryness under reduced pressure. 
The methanol insoluble material was extracted with water, and then lyophilized to yield the 
water extract. Purification and isolation of natural products was achieved through one or a 
combination of chromatographic techniques. 
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Scheme 1: A flow diagram representing preparation of extracts. 
Plant Material (powder) 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Isolation of natural products from M. flabellifolius 
2.4.1 Fractionation of the BuOH extract 
The BuOH extract (1 g) was dissolved in a mixture of methanol: dichloromethane (1:1), and 
then chromatographed on Sephadex LH-20 column. A mixture of methanol: dichloromethane 
MeOH solubles MeOH insolubles 
Water extract 
Hex 
extract 
Aqueous residue 
DCM extract Aqueous residue 
EtOAc extract 
Aqueous 
residue 
BuOH extract Aqueous 
residue 
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(1:1) [500ml] was used as an eluent. Fractions were collected and analyzed by TLC using a 
CHCl3:MeOH:H2O (200:52:6) mixture as eluent. Fractions labelled 4-9 showed similar TLC 
profiles, and thus were pooled together for further purification on the Sephadex column, 
using the same eluent as above. Fractions were collected and analyzed by TLC as previously 
described. Pooling of the relevant fractions resulted, after evaporation of the solvent, in the 
isolation of pure compound 1 (8.5 mg) as a faint yellow powder. 
 
Acetylation of compound 1 
Compound 1 (8.5 mg) was dissolved in a mixture of pyridine and acetic anhydride (2:1 v/v), 
and then stirred overnight at room temperature. To the mixture, an ice-water mixture (50ml) 
was added, followed by vigorous stirring for 0.5-1.0 hour. The mixture was extracted with 
70ml DCM, and the extract was washed twice with 50ml of water, alternating with 50ml of 
1.0M HCl each time, and then twice with water alone until free of pyridine and acetic acid. 
The DCM layer was dried over anhydrous Na2SO4, followed by solvent evaporation. The 
acetylated product was analyzed by NMR spectroscopy 
2.4.2 Fractionation of the EtOAc extract 
The EtOAc extract (10 g) was pre-adsorbed on silica gel before loading on a column. 
Fractionation was achieved through gravity column chromatography with the use of gradient 
elution. Eluents employed were 500ml volumes of DCM: EtOAc mixtures at ratios; (100:0), 
90:10), (80:20), (70:30), (60:40), (50:50), (40:60), (30:70), (20:80), (10:90), (0:100); 
followed by 500ml volumes of EtOAc: MeOH mixtures at ratios; (95:5), (90:10), (85:15), 
(80:20), (75:25), (70:30), (65:35), (60:40), (50:50), (40:60), (30:70), (20:80), (10:90), 
(0:100). Fractions were collected and analyzed by TLC using CHCl3:MeOH:H2O (200:52:6) 
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as an eluent mixture. Fractionation resulted in the isolation of pure compound 2 (23 mg) as a 
white crystalline material. 
 
2.4.3 Purification and fractionation of H2O extract 
Ethanol precipitation 
The water extract (10 g) was dissolved in water, and then ethanol was added to a final 
concentration of 80%. The mixture was centrifuged at 4000rpm for 20min. The centrifugate 
was redissolved in water and subjected to three more ethanol precipitations. The precipitate 
was washed with ethanol, centrifuged, and then dissolved in water and dialyzed. To obtain 
the crude polysaccharide (3.7 g), the precipitate was freeze dried. The crude polysaccharide 
(about 1 mg) was analyzed using FT-IR spectroscopy by incorporating the powdered material 
into KBr disc. The IR spectrum was recorded within the range of 4000-300 cm
-1
. 
 
Determination of Uronic Acid content 
The uronic acid content of the crude polysaccharide was determined by the carbazole assay. 
An aliquot of the polysaccharide solution (0.5 ml) at (100 μg/ml), standard solutions (5, 10, 
20, 40, 50 μg/ml of uronic acid) and control (distilled water) were placed in a test tube. 
Reagent A (1.8 mg sodium tetraborate decahydrate; 20 ml distilled water; 180 ml of 98% 
concentrated H2SO4 that was cooled in ice) (3 ml) was added to each and mixed. The closed 
tubes were shaken gently at first and then vigorously with constant cooling in an ice bath. 
The test tubes were heated at 100ºC for 10 minutes in a boiling water bath and then cooled 
rapidly in an ice-bath. Reagent B (100 mg carbazole; 100 ml absolute EtOH) (100 μl) was 
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then added. The samples were re-heated at 100ºC for 15 minutes, cooled rapidly to room 
temperature and the absorbance was measured at 525 nm on a spectrophotometer. 
 
Composition analysis of polysaccharides 
A standard mixture of known monosaccharides: rhamnose, arabinose, xylose, mannose, 
galactose and glucose (5 mg each) was dissolved in distilled water (3 ml). The mixture was 
reduced with 100mg of sodium borohydride (NaBH4). The mixture was converted into alditol 
acetates similarly to the polysaccharide rich fraction as described in (i). 
(i). The crude polysaccharide (5-50 mg) was hydrolyzed with 2M Trifluoroacetic acid (TFA) 
(2-5 ml) at 100°C. TFA was removed by successive addition and evaporation (5X) of MeOH. 
The residue was dissolved in 5 ml (4 H2O + 1 MeOH). 25% Aqueous ammonia solution (2 
drops) was added to neutralise residual TFA and then NaBH4 (~100 mg) was added. The 
contents were mixed by gentle swirling and allowed to stand overnight. The reaction mixture 
was acidified to ~pH 6 with drop wise addition of acetic acid followed by evaporation with 
MeOH as described above. To the resulting dry white/colourless residue, was added acetic 
anhydride (3-5 ml), and the mixture was heated at 100°C (steam bath) for 2 hours with 
occasional swirling.  
Crushed ice (~30 ml) was added, followed by vigorous stirring for 0.5-1 hour in order to 
destroy excess acetic anhydride. Addition of CHCl3 (~30 ml) was followed by vigorous 
shaking of the contents for about a minute, which were then transferred into a separating 
flask. Removal of the aqueous layer was followed by washing of the CHCl3 layer with 
distilled water (~20 ml) three times. Anhydrous Na2SO4 was added to dry the CHCl3 layer 
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(by allowing it to stand for 10-15 minutes with occasional swirling) and the Na2SO4 was 
filtered off. 
(ii) An aliquot of the reconstituted residue in CHCl3 was analysed using GC and GC-MS. A 
CHCl3 solution of the standard alditol acetates was injected in order to determine their 
retention times and mass. 
Methylation  
The following procedure was performed under nitrogen gas, using dry glassware, in order to 
minimize interaction with moisture. The crude polysaccharide (5-40mg) was dissolved in 2-
5ml of dimethyl sulfoxide (DMSO). To the mixture, NaOH powder (200-500mg) was added, 
followed by stirring for 1 hour. The sample mixture was frozen before the introduction of 
MeI (3-4ml). Upon addition of MeI, the flow rate of nitrogen gas was slowed down. The 
reaction mixture was then sealed with silicon septum and stirred overnight.  
The sample mixture was partitioned with water (7.5ml) and DCM (7.5ml) by shaking a 
separating funnel. The partitioning was repeated 3 times, and the organic layer was dried over 
Na2SO4. The methylation process was repeated by adding a mixture of Ag2O and 4ml of MeI 
followed by refluxing for two days at 40
0
C in order to ensure complete methylation. The 
resulting sample mixture was partitioned as described above. The organic phase was dried, 
and the methylated product was hydrolysed, reduced, acetylated and injected into a GC and 
GC-MS.   
Ion exchange chromatography 
The crude polysaccharide (1g) was chromatographed on a polyvinylpolypyrrolidone (PVPP) 
column and the resulting tannin-reduced fraction (100 mg) was purified on a DEAE 
Sepharose CL-6B ion exchange column, eluting stepwise with 70ml volumes of distilled 
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water and a NaCl gradient (0.1-1.0M) at a flow rate of 0.8 ml/min. Fractions (4ml) were 
collected, and for each fraction, the carbohydrate content was determined using the phenol-
sulfuric acid assay (Dubois et al.,1956). The carbohydrate containing fractions were pooled 
together, dialyzed and freeze-dried.  
 
Size exclusion chromatography 
The carbohydrate-rich fraction was further purified on a Sephacryl S-400 gel permeation 
column, eluting with NaCl (1M) and collecting 4mL fractions. For each fraction, the 
carbohydrate content was determined using the phenol-sulfuric acid assay. The column was 
calibrated using a mixture of Dextran standards [Amersham Biosciences] with known 
molecular weights (10,000 Da; 70,000 Da; 110,000 Da; 150,000 Da and 500,000 Da). 
 
2.5 Preparation of human serum albumin functionalized magnetic nanoparticles (HSA-
MNPs) (Lou et al, 2006) 
A mixture of 1M FeCl3 (8ml) and 0.5M Na2SO3 (4ml) was stirred under nitrogen. After a 
colour change from orange to yellow, 25% ammonia solution was added until pH 10. The 
colour of the resulting Fe3O4 solution changed to black. The solution was vigorously stirred 
for 15min, followed by separation and several washings with MeOH and de-ionized H2O. 
The Fe2O3 solution (2ml) was dispersed in a mixture of ethanol (80ml), de-ionized H2O 
(18ml) and concentrated ammonia solution (2.5ml), followed by addition of 0.5ml of 
tetraethyl orthosilicate (TEOS) under continuous stirring for about 8 hours. The silica coated 
nanoparticles were obtained through magnetic separation, with repeated washings (x4) with 
distilled water. The nanoparticles were then mixed in an ethanol solution (100ml) containing 
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0.1ml of 3-aminopropyltrimethoxysilane (APTMS). The mixture was stirred for 12 hours at 
60
o
C. The amino functionalized nanoparticles were obtained by magnetic separation, 
following repeated washings (x4) with ethanol. In a conical flask, the nanoparticles (5ml) 
were mixed with 15ml of the coupling buffer (10mM pyridine, pH 6.0), vortexed and 
followed by magnetic separation. The supernatant was discarded. The resulting beads were 
mixed with 20ml of glutaraldehyde solution containing the coupling buffer, followed by 
vortexing and gentle rotation for 3 hours. Magnetic separation led to the removal of the 
supernatant, followed by repeated washings (x3) of the beads with the coupling buffer. To the 
activated beads, HSA solution (50mg dissolved in 8ml of the coupling buffer) was 
introduced, followed by 24 hour gentle rotation at room temperature. The supernatant was 
removed through magnetic separation. An introduction of 20ml of the reaction-stop buffer 
(1M glutaric acid, pH 8.0) to the flask was followed by a 30min gentle rotation. The 
supernatant was removed through magnetic separation. The resulting nanoparticles were 
washed (x3) with the wash buffer (10mM Tris, pH 7.4) containing 0.15M NaCl, 1mM 
EDTA, 0.1% BSA, 0.1% sodium azide. The resulting HSA-MNPs were stored in ammonium 
10mM acetate buffer (pH 7.4) until further use. 
 
Ligand fishing from S. frutescens BuOH extract 
Ligand fishing was carried out following the procedure described by Qing et al. (2010).  A 
1.3mg/mL solution of the BuOH extract (S0) was prepared in 10mM ammonium acetate 
buffer (pH 7.4). A portion of S0 (1ml) and 100µl HSA-MNPs were transferred to a 4ml 
Eppendorf tube. The tube was vortexed for 30 min, and then put on a magnet for 5min to 
achieve a liquid–solid separation. The supernatant (S1) was carefully transferred to a test tube 
and saved. The HSA-MNPs was washed three times (using 1mL buffer each time) with 
 
 
 
 
41 
 
vigorously shaking for 2min. After liquid–solid separation, the supernatants were carefully 
collected and saved as solutions S2, S3 and S4, respectively. The fourth wash of the HSA-
MNPs was carried out with 1mL buffer containing 50% ACN for 2min. The supernatant was 
collected and saved as solution S5. In order to monitor the change of the components binding 
to HSA-MNPs, all the solutions were analyzed by LC-MS. 
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RESULTS AND DISCUSSION 
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CHAPTER 3 
IDENTIFICATION OF NATURAL PRODUCTS FROM Myrothamnus flabellifolius 
The isolation of natural products was carried out through a fractionation process as 
summarized in Scheme 2. 
 
Scheme 2: A flow diagram representing a summarized fractionation process that led to 
isolation of natural products. 
Plant powder (200g) 
 
 
 
 
 
 
 
 
 
 
 
Water extract  EtOAc extract  BuOH extract  
Crude polysaccharide 
(3.7 g) 
MPS (11mg) 
Compound 2 (23 mg) Compound 1 (8.5 mg) 
MPS-II 
(5.1mg) 
MPS-I 
(5.7mg) 
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3.1 Compound 1 (4-hydroxyphenyl-β-D-glucopyranoside; Arbutin) 
OR
O
O
ORRO
RO
RO 1
2
3
4
5
6
1'
2'
3'
4'
5'
6'
 
                  1: R=H 
                1a: R=Ac 
Compound 1 was obtained as a faint yellow powder. The negative ESIMS revealed a 
molecular ion [M-H]
-
 peak at m/z 271.0800, corresponding to the molecular formula 
C12H16O7. Compound 1 was identified as a phenolic glycoside on the basis of 
1
H and 
13
C 
NMR spectra (see Table 4, Appendix 1). The 
1
H NMR (600 MHz, CD3OD) spectrum 
revealed the presence of two symmetric 2-proton doublets at δ 6.71 (H-3, H-5, J=8.8 Hz) and 
6.96 (H-2, H-6, J=8.8 Hz), representing a para-disubstituted aromatic ring. The assignment of 
chemical shifts as H-2 and H-6 was made due to these being the more deshielded protons, as 
a result of their close proximity to the electron-deficient environment (created by the 
positioning of the glycosidic bond oxygen close to the sugar ring oxygen). H-3 and H-5 are 
less deshielded as a result of their close proximity to an electron-rich environment created by 
the aromatic ring hydroxyl group. Chemical shifts of a typical sugar moiety were also 
observed at δ 3.38 - 3.90 (6H), as well as a single-proton doublet at δ 4.75 (H-1’, J=6.0 Hz) 
representing an anomeric proton. H-1’ is the most deshielded proton of the sugar moiety 
protons since it is bonded to an anomeric carbon that is attached to two oxygen atoms, thus 
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positioned in an electron-deficient environment. The 
13
C NMR spectrum showed the presence 
of an anomeric carbon at δ 103.6 (C-1’). Four signals were observed in the aromatic region, 
C-1 at δ 153.7 and C-4 at δ 152.4, and the other two at δ 119.4 (C-2 and C-6) and δ 116.6 (C-
3 and C-5). The 
1
H and 
13
C NMR spectral data of compound 1 was similar to the data that 
had been reported for a known compound, arbutin, in the literature (Wiedenfeld et al., 2007). 
Table 4: 
1
H and 
13
C NMR Data (600 MHz, CD3OD) for compound 1 
Position δ C δ H 
1 153.7  
2/6 119.4 6.96 (d, J = 8.8 Hz) 
3/5 116.6 6.71 (d, J = 8.8 Hz) 
4 152.4  
1’ 103.6 4.75 (d, J = 6.0 Hz) 
2’ 74.9 3.38-3.45 (m) 
3’ 78.0 3.38-3.45 (m) 
4’ 71.4 3.38-3.45 (m) 
5’ 77.9 3.38-3.45 (m) 
6’a 62.5 3.90 (d, J = 12.0 Hz) 
6’b 62.5 3.62 (d, J = 7.0 Hz) 
The 
1
H NMR (200 MHz, CDCl3) spectrum of the acetylated compound 1 showed a 3-proton 
singlet at δ 2.27 which could be attributed to the phenolic acetate protons. Four more 3-
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proton singlets were observed at δ 2.06, 2.04, 2.03 and 2.01, and all could be attributed to the 
monosaccharide acetyl groups protons. In the aromatic region, the spectrum showed a 4-
proton singlet at δ 6.98 which could be assigned to the chemically equivalent aromatic 
protons. Acetylation of compound 1 led to a noticeable downfield shift of the proton signals 
as a result of the presence of electron-withdrawing acetyl groups, thus becoming more 
deshielded. The 
1H NMR data: δ6.98 (4H, s), 5.28-4.99 (4H, m), 4.27 (lH, dd, J=12.4 and 5.4 
Hz), 4.13 (lH,dd, J=12.4 and 2.7Hz), 2.27, 2.06, 2.04, 2.03, 2.01 (each 3H, s, 5 x OAc).  
The 
1
H NMR spectrum of the acetylated compound 1 was in agreement with that of an 
acetylated arbutin which was prepared from a commercially available sample. Therefore, 
compound 1 was confirmed to be arbutin. Arbutin had been isolated before from 
Myrothamnus flabellifolius in an acetylated form, i.e. as arbutin pentaacetate (Suau et al., 
1991) 
 
Arbutin is a naturally occurring hydroquinone derivative that is used as a skin lightening 
agent and has been reported to decrease the melanin formation by inhibiting tyrosinase 
activity (Maeda and Fukuda, 1996). It has also been reported that arbutin has antioxidant 
properties (Gerich, 2001), as well as antihyperglycaemic and antihyperlipidemic 
(Shahaboddin et al, 2011), antibacterial and antifungal activities (Kundakovic, 2014). The 
anti-ulcer activity of Turnera diffusa was attributed to arbutin’s immunomodulatory 
properties as well as lipid peroxidation inhibitory properties (Taha et al., 2012).  
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3.2 Compound 2 (Lupeol; 20(29) lupen-3β-ol) 
 
Compound 2 was obtained as a white crystalline material. It was identified as a pentacyclic 
triterpenoid on the basis of 
1
H and 
13
C NMR spectra (see Table 5, Appendix 2). The 
1
H NMR 
spectrum revealed two olefinic protons that appeared as broad singlets at δ 4.67 (1H, br s, H-
29b) and δ 4.54 (1H, br s, H-29a), which represent the exomethylene group. A doublet of 
doublet was observed at δ 3.12 (1H, dd, J=11.0 and 5.4 Hz, H-3) representative of the proton 
attached to the secondary carbon that is bonded to the hydroxyl group. A single proton signal 
was observed at δ 2.21 (1H, m, H-19). A broad 3-proton singlet was observed at δ 1.62 (3H, 
br s, H-30) indicating an isopropenyl function. The 
1
H NMR spectrum also showed six 3-
proton singlets at δ 0.75, 0.77, 0.83, 0.89, 0.90, 1.18 representatives of six tertiary methyl 
groups. The rest of the protons could be observed between δ 1.23 and δ 2.52 as complex 
multiplets.  
The 
13
C NMR spectrum of compound 2 showed that thirty signals, typical of a lupine-type 
triterpenoid skeleton. Two olefinic carbons of the exomethylene group appeared at δ 150.6 
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(C-20) and δ 109.8 (C-29), of which the olefinic carbon C-20 was the most deshielded. The 
spectrum also showed a signal at δ 79.1 (C-3) due to the carbon attached to a hydroxyl group. 
Table 5: 
13
C NMR Data (600 MHz, CDCl3) for compound 2 
Carbon δ C Carbon δ C Carbon δ C 
1 37.0 13 38.2 25 16.0 
2 29.7 14 42.3 26 15.7 
3 79.1 15 27.7 27 14.6 
4 38.2 16 35.5 28 18.3 
5 55.4 17 49.3 29 109.8 
6 18.3 18 46.7 30 19.2 
7 34.2 19 48.0 
8 40.9 20 150.6 
9 50.4 21 28.0 
10 42.3 22 35.6 
11 20.9 23 27.7 
12 25.7 24 14.6 
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Compound 2 was thus identified and confirmed to be lupeol after comparing its 
1
H and 
13
C 
NMR spectral data with the spectral data of the reported compound (Abdullahi et al, 2013; 
Prachayasittikul et al, 2010; Ravi and Venkatachalapathi, 2012; Venkata et al, 2012). To our 
knowledge, this is the first time that lupeol has been isolated from Myrothamnus 
flabellifolius. 
Lupeol has been reported to possess a wide range of health benefits, either as a preventive or 
therapeutic agent. Lupeol is known to exhibit antitumor, anti-inflammatory, antiprotozoal, 
antimicrobial and chemopreventive properties (Gallo and Sarachine, 2009). It has also been 
shown to be an active antiarthritic agent (Agarwal and Rangari, 2003), while its derivatives 
are active antimalarial agents (Kumar et al, 2008).   
 
3.3 Isolation and characterization of M. flabellifolius polysaccharides 
The water extract from M. flabellifolius was investigated for the presence of polysaccharides. 
Following ethanol precipitation, crude polysaccharides were obtained at 37% yield. The low 
yield suggests that the water extract predominantly contained low molecular weight material, 
such as disaccharides/oligosaccharides, which were removed during dialysis. The crude 
polysaccharides were examined by FT-IR spectroscopy. The FT-IR spectrum (see Fig 7) of 
the crude polysaccharides showed stretching frequencies at 1594 and 1375 cm
-1
, which are 
frequencies characteristic of the presence of the non-protonated carboxylate ion (COO
-
). The 
presence of the non-protonated carboxylate ion implies that the polysaccharides are possibly 
pectic in nature as suggested in literature (Moore et al., 2006). It also implies that the 
carboxylate ion could be associated with any of the following ions: Na
+
, K
+
, Ca
2+
, etc., since 
plants contain salts.  
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Figure 7: FT-IR spectrum of the crude polysaccharides. 
Confirmation of the presence of uronic acids was achieved through carbazole assay (see Fig 
8). The carbazole assay showed that the absorbance of the crude polysaccharides was 0.1021, 
which equated to approximately 15.7% of uronic acid content present in the crude 
polysaccharides, thus further confirming the possible pectic nature of the polysaccharides. 
 
Figure 8: Carbazole assay calibration curve at λ =525nm 
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Following the quantification of the uronic acid content, neutral sugar composition of the 
crude polysaccharide was determined through acid hydrolysis and GC analysis. Table 6 
highlights the neutral sugar composition of the crude polysaccharide. Glucose (Glc) is the 
most predominant sugar, accounting for 47.5% (relative mol percentage) of the total crude 
polysaccharide. The crude polysaccharide also consisted of other neutral sugars such as 
rhamnose (Rha), arabinose (Ara), xylose (Xyl), mannose (Man) and galactose (Gal) in 
concentrations of 1.6%, 7.5%, 3.3%. 3.3% and 21.1% respectively. 
 
Table 6: Neutral sugar composition of the crude polysaccharide 
Sugar Relative sugar composition (mol %) 
Ara 7.5 
Rha 1.6 
Xyl 3.3 
Man 3.3 
Gal 21.1 
Glc 47.5 
 
The crude polysaccharide was subjected to methylation and GC-MS analysis (see Appendix 
3) so as to determine the characteristic monosaccharide linkages. The monosaccharide 
linkage results are tabulated in Table 7. 
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Table 7: Linkage analysis of the crude polysaccharide 
Sugar Type of linkage Relative sugar composition 
(mol %) 
Ara 1,2           [→1)-Araf-(2→] 3.2 
 
 1,5           [→1)-Araf-(5→]  4.3 
Rha T              [Rhap-(1→] 0.4 
 1,2           [→1)-Rhap-(2→] 0.9 
 1,2,4        [→1,4)-Rhap-(2→] 0.3 
Xyl 1,2           [→1)-Xylf-(2→] 3.3 
Man T              [Manp-(1→] 1.3 
 1,2           [→1)-Manp-(2→] 1.4 
 1,2,4        [→1,4)-Manp-(2→] 0.6 
Gal T              [Galp-(1→] 7.2 
 1,3           [→1)-Gal-p(3→] 3.2 
 1,2           [→1)-Gal-p(2→] 1.7 
 1,4           [→1)-Gal-p(4→] 3.9 
 1,6           [→1)-Gal-p(6→] 3.5 
 1,3,6        [→1,3)-Galp-(6→] 1.6 
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Table 7: continued 
Sugar Type of linkage Relative sugar 
composition (mol %) 
Glc T        [Glcp-(1→] 14.2 
 1,3     [→1)-Glcp-(3→] 5.7 
 1,6     [→1)-Glcp-(6→] 12.2 
 1,4     [→1)-Glcp-(4→] 11.8 
 1,4,6  [→1,6)-Glcp-(4→] 3.6 
Uronic acid Nf Nf 
 nf = not found 
 
According to Table 7, the crude polysaccharide is made up of galactose units, of which 34% 
are terminal. About 58% of galactose units are 1,2-linked, 1,3-linked, 1,4-linked and 1,6-
linked. The remaining small portion of galactose units is 1,3,6-linked, thus showing some 
branching. Arabinose is present mainly as 1,2-linked and 1,5-linked. This suggests that there 
is a possible presence of arabinogalactans as a major constituent of the crude polysaccharide.  
Table 7 also shows that the crude polysaccharide also contained terminal, 1,2-linked and 
1,2,4-linked rhamnose units, a composition indicative of the presence of pectic 
polysaccharide. Xylose is found only as 1,2-linked residue, while mannose is present as 
terminal, 1,2-linked and 1,2,4-linked units. The presence of significant amounts of terminal, 
1,4-linked and 1,6-linked glucose units may suggest the presence of starch.  
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The linkages of the structural units with substituent uronic acids were not determined, the 
reason being that uronic acids will be converted into methyl esters during the methylation 
exercise, and the subsequent acid hydrolysis steps will convert the methyl esters into non-
volatile acids. The stability of the uronic acid-sugar linkages is such that the sugars linked 
with substituent uronic acids will not be fully released and therefore under estimated in both 
composition and linkage analysis. This led to an attempt to perform carboxyl reduction on the 
crude polysaccharide, followed by methylation and GC-MS analysis. Unfortunately, the 
PMAA’s derived from the carboxyl reduced sample could not be analysed in time to generate 
useful results to complement the structural elucidation because by the time they were 
analysed they had decomposed, and there was not sufficient time to repeat the sequence of 
the relevant experiments.  
 
The crude polysaccharide was purified on an ion exchange column, DEAE Sepharose CL-6B 
(calibrated with commercial pectin), and the resulting elution profile of the crude 
polysaccharide is shown in Fig 9. The elution profile revealed three polysaccharide 
containing fractions (labelled MPS, MPS-I and MPS-II) eluting at different NaCl 
concentrations, which suggests that the each of the fractions had a distinct ionic character. 
The fractions MPS, MPS-I and MPS-II eluted at 0.1-0.2M, 0.4-0.5M and 0.5-0.6M NaCl 
concentrations, respectively. The pectin standard eluted at 0.1-0.3M NaCl concentrations, and 
so it appears as though the early eluting MPS contains the pectin. The combined yields of the 
purified fractions; MPS (11% yield), MPS-I (5.7% yield) and MPS-II (5.1% yield), added up 
to about 22% of the polysaccharide content. It could be speculated that the low 
polysaccharide yield may be due to interactions between tannins and polysaccharides or 
between proteins and polysaccharides.  Moore et al (2007) reported that M. flabellifolius 
contains high levels of tannins. The free tannins were removed through fractionation of crude 
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polysaccharide (brown in colour) on a PVPP column. Following fractionation on PVPP, it 
was expected that the colour of the crude polysaccharide would change from brown to white. 
Instead, the crude polysaccharide appeared to be a faint orange colour, an indication that the 
crude polysaccharide could have been associated with either tannins or proteins. It has been 
reported that tannin-polysaccharide complexes are very stable and their structures depend on 
the tannin degree of polymerization (Carn et al, 2012). In a study by Chen et al (2008), a 
polysaccharide-protein complex was successfully isolated from a medicinal plant Lycium 
barbarum.  Upon purification on the DEAE sepharose column, there was a visible tinge of 
brown colour in the column after eluting with 1.0M NaCl which was indicative of material 
that was tightly bound to the DEAE sepharose. Therefore, the yield of the crude 
polysaccharide and that of the pure polysaccharide fractions could have been under estimated 
during the removal of free tannins and upon purification, respectively. 
 
Figure 9: Elution curve of the crude polysaccharide on DEAE Sepharose CL-6B 
achieved via phenol-sulfuric acid assay. 
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MPS was found to be the major polysaccharide fraction, followed by MPS-I and MPS-II. The 
fractions were compared for their sugar composition (see Table 8). The purified fractions 
revealed a significant decrease in the glucose molar concentration, when compared to that of 
the crude polysaccharide shown in Table 6, and an increase in molar concentrations of other 
sugars. This suggests that the purified polysaccharide fractions are free of salts and starch, a 
polysaccharide which is present in most plants. Neutral sugar composition of MPS shows that 
Rha (22.2%), Ara (26.8%) and Gal (26.1%) are the predominant sugars, accounting for 
approximately 75% of the neutral sugar content in the purified polysaccharide (see Table 8). 
The rest of the neutral sugar content of MPS is made up of Glc (5.7%), Xyl (14.8%) and Man 
(4.4%). The uronic acid content of MPS was determined (through carbazole assay) to be 
15.2%, almost the same as that of the crude polysaccharide. The MPS sugar composition is 
similar to that of the arabinose-rich pectic polysaccharides reported in literature (Moore et al., 
2006). Table 8 shows a significant increase in the Glc (14.2%), Man (10.6%) and Gal 
(35.3%) sugar concentrations in the purified polysaccharide MPS-I relative to those of MPS. 
However, MPS-I has a lower Rha (5.0%) and Xyl (7.2%) content. The highest Glc (21.7%), 
Rha (30.4%) and Man (28.2%) sugar content was observed in MPS-II. Table 8 also highlights 
that MPS-II did not contain any galactose, therefore MPS-II is a galactose-free 
polysaccharide. The uronic acid content of MPS-I and MPS-II could not be determined due to 
the low quantities of both polysaccharide fractions. 
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Table 8: Neutral sugar composition of purified polysaccharide fractions MPS, MPS-I 
and MPS-II 
Sugar Relative sugar composition (mol %) 
MPS MPS-I MPS-II 
Glc 5.7 14.2 21.7 
Rha 22.2 5.0 30.4 
Ara 26.8 27.7 10.5 
Xyl 14.8 7.2 9.2 
Man 4.4 10.6 28.2 
Gal 26.1 35.3 - 
 
The significant differences in the ionic character and neutral sugar composition between the 
purified polysaccharide fractions, confirm that three different polysaccharide types have been 
successfully isolated from M. flabellifolius. The low quantities of MPS-I and MPS-II made it 
impossible to further characterize these two polysaccharides. MPS was further fractionated 
on gel permeation chromatography, Sephacryl S-400, which was calibrated with Dextrans of 
known molecular weights. During fractionation, the small molecules (low molecular weight) 
get trapped in the gel pores and the larger molecules (higher molecular weight) flow through 
the gel. Thus, larger molecules elute first, followed by the smaller molecules in the order of 
their sizes (Garrett and Grisham, 1999). Fractions (2 ml) were collected and their 
carbohydrate content was determined through phenol-sulfuric acid assay. Figure 10 shows 
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that the fractionation of MPS led to the separation of a major peak, MPS-A, which eluted 
first. The void volume of the column (V0) was 43 ml. Several minor fractions of different 
molecular weights eluted later. The last peak, at 354 ml, represents the sugar with the lowest 
molecular weight. The total volume of the column was 383 ml. 
 
Figure 10: Elution curve of MPS on Sephacryl S-400 achieved via phenol-sulfuric acid 
assay 
 
The molecular weight distribution of polysaccharide-containing fraction, MPS-A, was 
determined using the Dextran calibration curve (see Fig 11). Using the formula: Log (Mw) = 
-0.0227x + 6.3424; where Mw and x represent the molecular weight and the elution volume, 
respectively, the molecular weight of MPS-A was estimated at 2 X 10
5
 Da. 
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Figure 11: Dextran Calibration curve for determining molecular weight distribution. 
 
Determination of molecular weight distribution in polysaccharides is of utmost importance 
because molecular size of polysaccharides is often closely related to their biological activity. 
It was reported that the polysaccharide molecular weight determines the levan antitumour 
activities and that a specific class of molecular weight may be responsible for this effect 
(Calazans et al., 2000). The ionic character in some polysaccharides is also correlated with 
their biological activity. It was reported that the more flexible pectin hairy regions were 
responsible for the biological activities (Ognyanov et al., 2013). Therefore, molecular weight 
distribution and uronic acid composition are important for quality control of polysaccharides. 
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CHAPTER 4 
Ligand fishing from Sutherlandia frutescens extract 
The four flavonol glycosides and four saponins (see Fig 12) which had been isolated 
following lengthy and laborious chromatographic separation techniques, from the butanol 
extracts of S frutescens (Fu et al., 2010; Fu et al., 2008) were targeted for this particular 
study. 
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Figure 12: Chemical structures of the leaf constituents isolated from S. frutescens. (1) 
sutherlandin A, (2) sutherlandin B, (3) sutherlandin C, (4) sutherlandin D, (5) 
sutherlandioside B, (6) sutherlandioside C, (7) sutherlandioside A and (8) sutherlandioside D. 
 
It is believed that the flavonol glycosides and saponins isolated from S. frutescens are 
responsible for the plant’s wide usage in the prevention and treatment of cancer and HIV 
(Kikuchi et al., 2007; Tai et al., 2004). 
In this study, human serum albumin functionalized magnetic nanoparticles (HSA-MNPs) 
were used in order to investigate the possible isolation of flavonol glycosides and saponins 
from S. frutescens butanol extract. The analysis of the extract was performed using LC-MS 
(ESI-MS positive mode). ESI-MS analysis of the butanol extract (solution S0) revealed the 
presence of a large number of compounds (see Fig 13).  
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Figure 13: LC-ESI-MS profile of S. frutescens butanol extract (S0). Peak identification 
was done in accordance to the numbering of chemical structures in Fig 12.  
 
As shown in the chromatogram (Fig 13), eight peaks could be assigned as follows: m/z 741.2 
[M+H]
+
 sutherlandin A (1), m/z 741.2 [M+H]
+
 sutherlandin B (2), m/z 725.2 [M+H]
+
 
sutherlandin C (3), m/z 725.2 [M+H]
+
 sutherlandin D (4), m/z 670.5 [M+NH4]
+
 
sutherlandioside B (5), m/z 668.4 [M+NH4]
+
 sutherlandioside C (6), m/z 670.5 [M+NH4]
+
 
sutherlandioside A (7) and m/z 635.4 [M+H]
+
 sutherlandioside D (8). Previous studies on S. 
frutescens did not show the presence of any isomers of the compounds in Fig 12. 
Furthermore, Fig 13 shows that the identified compounds do not have any isomers. The 
identification of flavonol glycosides and saponins in the butanol extract of S. frutescens could 
be developed as a quality control protocol by using LC-MS.  
Following the first liquid-solid separation of HSA-MNPs, ESI-MS analysis of solution S1 
resulted, as judged qualitatively, in a similar chromatographic profile to that of solution S0. 
Thus all the peaks that were observed in Fig 13 could also be found to be present in the 
Polar 
Non-polar  
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chromatogram representing solution S1 (see Fig 14). The similarity in chromatographic 
profiles could be attributed to the HSA-MNPs being saturated with the constituents present in 
solution S0. 
 
 
Figure 14: LC-ESI-MS profile of solution S1 from HSA-MNPs 
From the chromatographic profiles of solutions S0 and S1, it could be observed that in the 
polar and non-polar regions, the most prominent peaks were those representing compounds 3 
and 6, respectively. A similar pattern was also observed after the analysis of solution S2 (see 
Fig 15). 
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Figure 15: LC-ESI-MS profile of solution S2 from HSA-MNPs 
 
Following the second washing of HSA-MNPs with the buffer, analysis of solution S3 showed 
a noticeable change in the pattern in the non-polar region. The peak representing compound 5 
was greatly enhanced to such an extent that it had become the most prominent peak (see Fig 
16). The peak representing compound 6 was slightly reduced. 
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Figure 16: LC-ESI-MS profile of solution S3 from HSA-MNPs 
Analysis of solution S4 showed further reduction in the compound 6 peak, and a 
disappearance of the peak representing compound 7 (see Fig 17). 
 
Figure 17: LC-ESI-MS profile of solution S4 from HSA-MNPs 
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Following the washing of HSA-MNPs with a mixture of the buffer containing 50% ACN, the 
chromatogram of solution S5 showed the presence of five compounds (see Fig 18) which 
were identified as; sutherlandin C (3), sutherlandioside B (5), sutherlandioside C (6), 
sutherlandioside A (7) and sutherlandioside D (8). Thus, the five compounds showed an 
affinity to bind strongly but reversibly to HSA immobilized on MNPs. The other three 
compounds identified in the butanol extract, i.e. sutherlandin A (1), sutherlandin B (2) and 
sutherlandin D (4) were not detected.  
 
 
Figure 18: LC-ESI-MS (positive mode) analysis of the 50% ACN eluent (solution S5) 
from HSA-MNPs. 
 
The three flavonol glycosides (sutherlandin A, B and D) may have not been detected because 
of one or a combination of the following;  
i. Present in very low concentrations 
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ii. Possibility of irreversible binding 
 
Comparing the chromatograms from solution S0 through to solution S5, it is evident that the 
peak abundance is greatly enhanced for sutherlandiosides B (5) and D (8). These results may 
suggest that sutherlandiosides B and D may have a higher affinity to bind reversibly to HSA. 
Sutherlandioside B is the major saponin isolated from S. frutescens (Fu et al., 2008). Fig 18 
shows that it is also the most predominant after ligand fishing. The molecular formula of 
sutherlandioside B was determined to be C36H60O10 by mass spectroscopy (m/z 652.4186). 
The MS
2
 spectrum of sutherlandioside B gave fragment ions at m/z 635.4126, indicating the 
loss of a water molecule (see Fig 19). The MS
3
 spectrum of the m/z 635.4126 showed 
fragment ions at m/z 491.3742, indicating the loss of a glucosyl moiety. 
   
 
Figure 19: Fragmentation pathways for sutherlandioside B.  
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These results show that the use of HSA as a ‘receptor’ to extract ligands from S. frutescens is 
depended on the structural characteristics of the bioactive components present. As such, the 
procedure proved to be biased towards specific structural characteristics, as evidenced by the 
simple spectrum (Fig 18) compared to that of the crude butanol extract. Therefore, this 
procedure could be used as a pre-treatment of crude extracts to prepare for MS 
characterization. 
Because the HSA binders were identified to be saponins (triterpenoid glycosides), the ligand 
fishing procedure was attempted on the butanol extract of M. flabellifolius since arbutin, a 
phenolic glycoside, was isolated from it. Unlike saponins, arbutin did not show any binding 
affinity towards HSA. 
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CHAPTER 5 
CONCLUSIONS 
Isolation of some natural products from Myrothamnus flabellifolius was carried out 
successfully. Two compounds, arbutin, a phenolic glycoside, and lupeol, a triterpenoid, were 
isolated and fully characterized. The water extract was found to contain a heterogeneous 
mixture of polysaccharides which included those of the pectic type, where the latter could be 
separated into three polysaccharide fractions, MPS, MPS-I and MPS-II. The isolated natural 
products have been reported to exhibit some important biological activities, some of which 
include; antibacterial, antifungal, immunomodulatory, antioxidant, antihyperglycaemic, 
antihyperlipidemic, antitumor, anti-inflammatory, antiprotozoal, antimicrobial, 
chemopreventive, antimalarial, antiarthritic, antitumor, etc. Therefore, the isolated bioactive 
compounds validate the use of M. flabellifolius as a nutritious herbal tea. Furthermore, there 
is a great possibility that more bioactive compounds may still be isolated from M. 
flabelliffolius, with the use of a variety of organic extracts. Biological activity tests of the 
various extracts will also provide very useful information, and so should toxicology studies.  
It has been reported in literature that natural products such as 3,4,5-tri-O-galloylquinic acid, 
trehalose, pinocarvone and trans-pinocarveol were isolated from M. flabellifolius. However, 
such natural product composition differs from what has been reported in this thesis. This 
difference in natural product composition might be due to differences in geographical 
location, the nature of the soil, seasonal collection and/or climate in which the plant grows. 
Or it might be due to differences in plant extraction techniques employed. 
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The use of human serum albumin (HSA) following its anchoring on magnetic nanoparticles, 
for the purpose of isolating identified saponins from Sutherlandia frutescens was shown to be 
a potentially useful method for further exploration towards purification of the individual 
saponins for pharmacological studies, given that the four reported saponins, namely 
sutherlandiosides A, B, C and D showed a good affinity to bind to the HSA. An investigation 
of association/dissociation constants between HSA and these saponins would probably 
provide a better insight into their importance in pharmacological activity, and so should a 
statistical analysis of their binding capacity. Molecular modelling might as well provide 
valuable information. Exploring different buffer systems may help improve drug-protein 
binding, e.g. the case where arbutin did not show any binding affinity towards HSA, because 
the protein binding behaviour is influenced by the type of buffer system in solution with the 
protein. 
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APPENDIX 
Appendix 1a 
1
H NMR of compound 1 
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Appendix 1b 
13
C NMR of compound 1 
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Appendix 2a 
1
H NMR of compound 2 
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Appendix 2b 
13
C NMR of compound 2 
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Appendix 3a Chromatogram of the partially methylated alditol acetates 
1 0 . 0 0 1 5 . 0 0 2 0 . 0 0 2 5 . 0 0 3 0 . 0 0 3 5 . 0 0 4 0 . 0 0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 0 0 0 0 0 0
   1 e + 0 7
 1 . 1 e + 0 7
 1 . 2 e + 0 7
 1 . 3 e + 0 7
 1 . 4 e + 0 7
 1 . 5 e + 0 7
 1 . 6 e + 0 7
 1 . 7 e + 0 7
 1 . 8 e + 0 7
 1 . 9 e + 0 7
   2 e + 0 7
 2 . 1 e + 0 7
 2 . 2 e + 0 7
 2 . 3 e + 0 7
 2 . 4 e + 0 7
 2 . 5 e + 0 7
T i m e - - >
A b u n d a n c e
T I C :  W T M _ S a m p l e _ 4 . D \ d a t a . m s
1 6 . 0 7 9
1 6 . 4 8 8
1 7 . 5 1 0
1 8 . 5 5 9
1 8 . 9 6 5
1 9 . 8 5 4
2 0 . 0 0 2
2 0 . 4 2 5
2 0 . 5 0 1
2 0 . 6 1 52 0 . 7 2 4
2 0 . 8 7 5
2 1 . 0 1 2
2 1 . 3 6 52 1 . 4 0 5
2 1 . 9 9 8
2 2 . 3 4 9
2 2 . 5 4 9
2 2 . 7 4 52 2 . 8 6 62 3 . 1 3 9
2 3 . 3 9 1
2 3 . 4 7 5
2 3 . 5 9 2
2 3 . 8 8 9
2 3 . 9 7 5
2 4 . 3 8 3
2 4 . 4 1 9
2 4 . 7 6 1
2 5 . 0 3 3
2 5 . 1 3 0
2 5 . 2 0 2
2 5 . 3 2 6
2 5 . 4 5 8
2 5 . 5 4 5
2 5 . 7 8 4
2 5 . 9 1 6
2 6 . 2 0 3
2 6 . 4 0 3
2 6 . 5 8 3
2 6 . 6 5 8
2 6 . 7 0 3
2 6 . 7 6 6
2 6 . 9 9 5
2 7 . 2 3 2
2 7 . 3 7 1
2 7 . 4 0 9
2 7 . 6 5 7
2 7 . 7 5 5
2 7 . 8 4 5
2 7 . 9 4 7
2 7 . 9 9 3
2 8 . 3 4 22 8 . 4 0 52 8 . 6 5 9
2 9 . 1 1 3
2 9 . 1 5 4
2 9 . 4 4 1
2 9 . 5 0 8
2 9 . 7 8 6
3 0 . 0 1 0
3 0 . 2 5 03 0 . 5 4 7
3 0 . 6 7 5
3 0 . 7 8 4
3 1 . 1 2 1
3 1 . 5 1 73 1 . 7 6 03 2 . 0 8 7
3 2 . 3 1 63 2 . 3 9 5
3 2 . 9 4 03 3 . 2 7 23 3 . 4 9 13 3 . 8 5 7
3 4 . 3 9 8
3 6 . 1 8 1
3 6 . 5 2 6
3 8 . 3 5 4
3 8 . 5 7 7
4 1 . 2 7 3
4 2 . 2 3 0
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Appendix 3b Mass spectrum of →1)-Araf-(2→ 
50 100 150 200 250 300 350 400 450
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
m/ z-->
Abundanc e
Sc an 3451 (26.201 min): W T M _Sample_4.D \ data.ms
129.143.1
161.1
85.1
309.4
205.2
239.3 273.3 384.1 458.1348.4
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Appendix 3c Mass spectrum of →1)-Araf-(5→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  3658  (27 .408  min ): W T M _Sample_4 .D \ da ta .ms
117.143 .1
189.1
81 .1
152.1 233.2 303.3 458.2384.2348.2268.3 499.1
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Appendix 3d Mass spectrum of Rhap-(1→ 
50 100 150 200 250 300 350 400 450
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
m/ z-->
Abundanc e
Sc an 3301 (25.327 min): W T M _Sample_4.D \ data.ms
43.1
101.1
161.1
131.1
195.1 288.3233.2 458.0384.2320.3
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Appendix 3e Mass spectrum of →1)-Rhap-(2→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundance
Scan 3529 (26.656 min): W TM_Sample_4.D \ data.ms
43.1
131.1
89.1
165.1
249.2
205.2 323.3289.3 458.2384.0 499.3
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Appendix 3f Mass spectrum of →1,4)-Rhap-(2→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  3898  (28 .807  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
129.1
87 .1
189.1
247.1 384.0303.2 458.2346.2 499.2
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Appendix 3g Mass spectrum of →1)-Xylf-(2→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  3718  (27 .758  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117.1
189.1
81 .1
337.4153.1 233.2 277.1 384.1 458.2 499.3
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
Appendix 3h Mass spectrum of Manp-(1→ 
50 100 150 200 250 300 350 400 450
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
m/ z-->
Abundanc e
Sc an 3537 (26.703 min): W T M _Sample_4.D \ data.ms
43.1 101.1
145.1
205.1
175.2 263.3 318.3 458.2384.0348.4
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Appendix 3i Mass spectrum of →1)-Manp-(2→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an 3958 (29.157 min): W T M _Sample_4.D \ data.ms
43.1
129.1
87.1
189.1
223.1261.1
340.3 458.2384.0303.3 499.4
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Appendix 3j Mass spectrum of →1,4)-Manp-(2→ 
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
m/ z-->
A b u n d a n c e
S c a n  4 5 1 4  (3 2 .3 9 7  min ): W T M _ S a mp le _ 4 .D \ d a ta .ms
4 3 .1
1 2 9 .1
9 1 .1
1 8 9 .1
2 3 3 .1
2 8 9 .1
3 8 4 .2 4 5 8 .13 4 5 .3 4 9 9 .5 5 4 6 .34 2 1 .5
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Appendix 3k Mass spectrum of Galp-(1→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an 3701 (27.659 min): W T M _Sample_4.D \ data.ms
43.1
101.1
145.1
205.2
277.2 337.4239.2 458.2384.2 499.2
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Appendix 3l Mass spectrum of →1)-Gal-p(3→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4007  (29 .442  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117 .1
233 .1
161 .1
81 .1
277 .1197 .1 458 .0322 .4 384 .0 499 .1
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Appendix 3m Mass spectrum of →1)-Gal-p(2→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4035  (29 .605  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
101 .1
189 .1
147 .1
233 .1
458 .2384 .1315 .2275 .3 499 .3534 .3
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Appendix 3n Mass spectrum of →1)-Gal-p(4→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4066  (29 .786  min ): W T M _Samp le_4 .D \ da ta .ms
43 .1
117 .1
233 .1
81 .1
161 .1
197 .1 277 .2 339 .3 384 .2 458 .1 499 .1
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Appendix 3o Mass spectrum of →1)-Gal-p(6→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4405  (31 .762  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117 .1
161 .181 .1
219 .1
305 .1 458 .1384 .1261 .3 347 .4 499 .1419 .4
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Appendix 3p Mass spectrum of →1,3)-Galp-(6→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4857 (34 .397  min): W T M _Sample_4 .D \ da ta .ms
43.1
117 .1
189 .1
233 .1
81 .1
153 .1 305 .1269 .2 384 .1 458 .3343 .5 499 .1
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Appendix 3q Mass spectrum of Glcp-(1→ 
50 100 150 200 250 300 350 400 450
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
m/ z-->
Abundanc e
Sc an 3628 (27.233 min): W T M _Sample_4.D \ data.ms
101.1
43.1
161.1
205.2
131.1
263.2 316.3 384.1346.3 458.2
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Appendix 3r Mass spectrum of →1)-Glcp-(3→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  3951  (29 .116  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117.1
161.1
233.1
81 .1
277.2197.1 458.2365.4315.2 499.3404.2
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Appendix 3s Mass spectrum of →1)-Glcp-(6→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4104  (30 .008  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117 .1
233 .1
161 .1
81 .1
291 .2 365 .4197 .2 458 .2327 .3 402 .3 499 .2
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Appendix 3t Mass spectrum of →1)-Glcp-(4→ 
50 100 150 200 250 300 350 400 450 500
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundanc e
Sc an  4295  (31 .121  min ): W T M _Sample_4 .D \ da ta .ms
43 .1
117.1
189.1
233.1
81 .1 153.1 291.2 458.2375.2331.3 499.2415.1
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Appendix 3u Mass spectrum of →1,6)-Glcp-(4→ 
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
m/ z-->
A b u n d a n c e
S c a n  4 7 6 4  (3 3 .8 5 4  min ): W T M _ S a mp le _ 4 .D \ d a ta .ms
4 3 .1
1 1 7 .1
2 0 2 .1
2 6 1 .18 1 .1
1 5 9 .1
3 8 4 .23 1 0 .3 4 5 8 .1 5 0 0 .13 4 7 .1 4 2 0 .5 5 4 0 .7
 
 
 
 
 
 
 
 
 
 
 
 
